April 11 Leap Therapeutics announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12.66M shares of its common stock at a price of $2.82 per share and pre-funded warrants to purchase 1.52M shares of common stock at a price of $2.819 per share of common stock issuable upon exercise of the pre-funded warrants, in a private placement. Leap anticipates the gross proceeds from the private placement will be approxi...
$Leap Therapeutics(LPTX.US)$ NEWS LEAP THERAPEUTICS ANNOUNCES $40 MILLION PRIVATE PLACEMENT INTENDS TO USE NET PROCEEDS FROM FINANCING TO FUND CONTINUED DEVELOPMENT OF ITS LEAD MONOCLONAL ANTIBODY PROGRAM, DKN-01
$Leap Therapeutics(LPTX.US)$Leap Therapeutics Concludes Enrollment In The Randomized Controlled Part C Of Distinguish Study Of DKN-01 In Combination With BeiGene's Tislelizumab And Chemotherapy In Patients With Advanced Gastroesophageal Junction And Gastric Cancer Benzinga· 1 min ago
Jaguar8 : Love it
Trytosaveabit楼主 Jaguar8: Right! What’s Gilead up to? Hehehe
Jaguar8 Trytosaveabit楼主: I sense they will eventually buy this out
买跌不追涨 : 今天可以早点休息吧,别这么累。周末愉快
BelleWeather : Interesting choice. I’m going to do DD with a focus on the science. I hope it pans out and they get bought out.
查看更多评论...